Table 1.

Key features of included trials.

	Beta-blocker	Control	Design	Administration	Major inclusion criteria	Major exclusion criteria
BEAT-AMI5	Esmolol infusion for target HR of 60/min	Placebo	Single center 1:1 randomized, single-blind, placebo-controlled	60 min after PCI	STEMI patients with successful PCI, symptom onset to PCI<6 h	Killip class III or IV, HR <60/min, mean arterial BP<65 mm Hg
EARLY-BAMI6	Metoprolol 2 intravenous doses of 5 mg	Placebo	International multicenter 1:1 randomized, double-blind, placebo-controlled	First bolus in ambulance. Second bolus at immediately before PCI	STEMI patients eligible for primary PCI, symptoms >30 min to <12 h	Killip class III and IV, HR<60/min, systolic BP<100 mm Hg, type II or III AV-block
Hanada et al.7	Landiolol 3 µg/kg/min infusion for 24 h, no loading dose	Routine care	Single-center: 1:1 randomized, non-blinded, open-label	Directly after PCI	STEMI patients undergoing primary PCI, symptoms for <12 h	Killip class III or IV, HR<50/min, systolic BP<90 mm Hg, type II or III AV-block
METOCARD-CINC8	Metoprolol up to 3 intravenous doses of 5 mg	Routine care	Multicenter 1:1, randomized, single-blind	During transfer to PCI or at the emergency department	Anterior STEMI patients, symptom onset >30 min to <4.5 h	Killip class II or IV, HR<60/min, systolic BP<120 mm Hg, type II–III AV-block

AV: atrioventricular; BEAT-AMI: BEtA-Blocker Therapy in Acute Myocardial Infarction; BP: blood pressure; EARLY-BMI: Early Beta-blocker Administration before primary PCI in patients with ST-elevation Myocardial Infarction; HR: heart rate; METOCARD-CNIC: Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction.